NVAX Stock – Arrival of Covovax vaccine doses to commence Q3 2021 – The Manila Times
MILLIONS of Filipinos stand to benefit from the promising results of Covovax, licensed by Novavax, following the global announcement of final efficacy analysis of the United Kingdom (UK) Phase 3 trials of the said vaccine on Tuesday (Philippine time).
Philippine Covovax distributor Faberco Life Sciences, citing the results released by Novavax in the United States today said the vaccine provides 100-percent protection against severe cases of Covid-19 and 96.4-percent efficacy against the original strain of Covid-19.
The UK Phase 3 trials also concluded that CovovaxTM registered a 90.9-percent efficacy in adults with high-risk medical comorbidities and 88.9-percent efficacy in adults over the age of 65 years old.
Likewise, the trials results confirmed that the vaccine provides 100-percent protection against severe diseases caused by the South African and UK variants of Covid-19. It also showed 86.3-percent efficacy against the B.1.1.7 UK variant and 55.4-percent efficacy among HIV-negative participants with the vast majority of cases due to the B.1.351 South African escape variant.
Based on the operational highlights released this morning by Novavax (Philippine Time), “the UK Phase 3 results are now submitted for publication. South Africa Phase 2b results were published in the prestigious New England Journal of Medicine.”
Due to the encouraging results, numerous studies have been expanded to include adolescents (12 to 17 years old) and pregnant women as well as on its potential use as a booster in combination with other Covid-19 vaccines and for seasonal revaccinations.